Search
Cyclophosphamide Treatment Options in Massachusetts
A collection of 405 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the Massachusetts, United States. Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.
337 - 348 of 405
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
Completed
In small initial studies, combined kidney and bone marrow transplants from the same donor have permitted some individuals to stop taking anti-rejection medicines without rejecting their transplant. This clinical trial will study this method in a greater number of people to determine if it is indeed effective and safe.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
11/06/2015
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Kidney Transplantation, Kidney Failure, Chronic
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Completed
The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of subjects with unresectable stage III non-small cell lung cancer, compared to best supportive care alone.
A local ancillary (sub) study in European centers will evaluate the immune response in peripheral blood after tecemotide (L-BLP25) or placebo vaccination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2015
Locations: Lahey Clinic, Burlington, Massachusetts
Conditions: Non-small Cell Lung Cancer
Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer
Completed
The purpose of this study is to find out what effects (good and bad) a combination of cytoxan, epirubicin, and capecitabine have on women with Stage II/II/IIIA breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/23/2015
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy and radiation therapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and radiation therapy and kill more cancer cells. It is not yet known which treatment regimen is more effective for multiple myeloma.
PURPOSE: Randomized phase III tri... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/05/2015
Locations: New England Medical Center Hospital, Boston, Massachusetts +1 locations
Conditions: Multiple Myeloma
S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of tumor cells by stopping blood flow to the tumor. It is not yet known if combination chemotherapy is more effective with or without thalidomide for multiple myeloma.
PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without thalidomide in treating patients who have refractory multiple myeloma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2015
Locations: Boston Medical Center, Boston, Massachusetts +1 locations
Conditions: Multiple Myeloma
S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia
Completed
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. It is not yet known if total-body irradiation plus peripheral stem cell transplantation is more effective with busulfan or with cyclophosphamide for myelodysplastic syndrome or acute myeloid leukemia.
PURPOSE: Randomized phase III trial to compare the effectiveness of busulfan with that of cyclophosphamide in patients undergoing t... Read More
Gender:
ALL
Ages:
Between 16 years and 55 years
Trial Updated:
03/05/2015
Locations: Boston Medical Center, Boston, Massachusetts +1 locations
Conditions: Leukemia, Myelodysplastic Syndromes
SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with or without bone marrow transplantation in treating patients who have acute lymphocytic leukemia.
Gender:
ALL
Ages:
Between 15 years and 65 years
Trial Updated:
03/05/2015
Locations: Boston Medical Center, Boston, Massachusetts +1 locations
Conditions: Leukemia, Neutropenia, Thrombocytopenia
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
Terminated
This phase II trial is studying how well giving bortezomib together with liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide works in treating patients with multiple myeloma that relapsed after autologous stem cell transplant. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide, work in different ways to stop the grow... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/05/2015
Locations: Eastern Cooperative Oncology Group, Boston, Massachusetts
Conditions: Refractory Multiple Myeloma
Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Completed
This phase II trial studies how well giving imatinib mesylate together with chemotherapy and peripheral stem cell transplantation works in treating patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Giving imatinib mesylate together with chemotherapy and peripheral ste... Read More
Gender:
ALL
Ages:
Between 15 years and 59 years
Trial Updated:
11/13/2014
Locations: Beverly Hospital, Beverly, Massachusetts +2 locations
Conditions: Adult Acute Lymphoblastic Leukemia in Remission
Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma
Completed
This phase II trial is studying how well giving rituximab together with combination chemotherapy and bortezomib works in treating patients with untreated mantle cell lymphoma. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and dexameth... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2014
Locations: Eastern Cooperative Oncology Group, Boston, Massachusetts
Conditions: Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
Completed
RATIONALE: Drugs used in chemotherapy, such as etoposide and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Thalidomide, celecoxib, and fenofibrate may stop the growth of cancer cells by blocking blood flow to the cancer. Celecoxib also may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with thalidomide, celecoxib, and feno... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
09/19/2014
Locations: Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Central Nervous System Tumor, Pediatric, Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma
Terminated
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy before surgery may shrink the tumor so that it can be removed. Giving combination chemotherapy after surgery may kill any remaining tumor cells.
PURPOSE: This phase II trial is studying how well surgery and/or combination chemotherapy work in treating children with fibrosarcoma.
Gender:
ALL
Ages:
2 years and below
Trial Updated:
09/16/2014
Locations: Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Sarcoma
337 - 348 of 405